Rising awareness among general population about diseases such as cancer, liver diseases and uterine fibroids has exponentially increased the demand for CA 125 test
Rising awareness among general population about diseases such as cancer, liver diseases and uterine fibroids has exponentially increased the demand for CA 125 test
Fact.MR, Rockville MD: Rise in prevalence of ovarian cancer among women and increasing emphasis on healthcare are the key drivers for the global CA 125 test market, evaluates Fact.MR in its latest report. Ongoing research and development activities and rising demand for cancer screening biomarker devices to bolster the demand for CA 125 test.
Increasing awareness about cancer and other chronic medical conditions such as uterine fibroids and fallopian tube cancer can cause rise of CA 125 level in blood, aiding the demand for CA 125 tests. For instance, according to American Cancer Society study in 2020, around 22,000 women are likely to be diagnosed with ovarian cancer, while the mortality rate being higher among them, which is aiding the CA 125 test sales.
“Rising cases of ovarian cancer, fallopian tube cancer and women with advanced stage of cancer are likely to have increased CA 125 levels in blood which is prompting the patients to take CA 125 level test,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5259
Key Takeaways
- Based on indication, cancer is expected to witness highest growth
- In terms of end-user, diagnostic centers to be the most lucrative segment
- United States expected to remain dominant owing to the increased prevalence of cancer
- Extensive R&D activities to foster CA 125 test demand in UK
- India and China to lead the Asia Pacific market owing to the increasing cases of cancer in the region
- Rising cases of ovarian cancer in France to lead the European market
Prominent Drivers
- Government initiatives and favorable reimbursement policies to boost the treatment adoption
- Rise in prevalence of ovarian cancer and early diagnosis treatment to be a major driver for CA 125 test
Key Restraints
- Lack of awareness of diagnostic test and high cost of treatment to hamper the growth of the market
Discover more about the CA 125 test market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/5259/ca-125-test-market
Competitive Landscape
Abbott Laboratories, , Bayer, Eli Lilly Company, Allergan plc, Amgen Inc., Pfizer Inc., Merck & Co., Inc., Teva Pharmaceuticals Pvt. Ltd., AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis AG, AbbVie Inc., GlaxoSmithKline plc among others are some of the key players profiled by Fact.MR.
In February 2021, Celsion’s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer.
Simultaneously, in the same year InVivo analytics granted US$1.7 million to advance preclinical 3D imaging, develop and commercialize its next-gen fluorescence.
More Insights on the CA 125 test Market
In its latest market research study, Fact.MR gives a detailed segmentation on the global CA 125 test. In order to understand the scope of the market, drivers and challenges, the market is segmented on the basis of indication (cancer, endometriosis, uterine fibroids, liver diseases, and others), end-user (hospitals, clinics, diagnostic centers and others) and regions (North America, Latin America, South Asia, East Asia, Oceania and Middle East & Africa)
Request more information about Report Methodology
https://www.factmr.com/connectus/sample?flag=RM&rep_id=5259
Explore Fact.MR’s Coverage on the Healthcare Domain
Ovarian cancer diagnostics Market: Fact.MR’s recent study on the global ovarian cancer diagnostics offers 10-year forecast. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, challenges and opportunities for key market players along with key stakeholders and emerging players.
Kidney Cancer Diagnostics Market: Fact.MR’s exhaustive analysis on global kidney cancer diagnostics market offers value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Blood Cancer Diagnostics Market: Fact.MR has published a detailed research study on the global market for blood cancer diagnostics. The study provides an in-depth analysis on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the blood cancer diagnostics market structure.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR